^
    Back
    Association details:
    Biomarker:BCL2 positive
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Tavalisse (fostamatinib) (SYK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2018
    Title:

    SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL

    Published date:
    11/01/2018
    Excerpt:
    Significant synergistic activity was seen in all five BCL-2-positive/SHP1-negative GCB DLBCL cell lines with the R406 + venetoclax combination and in four of them with the ibrutinib + venetoclax combination….Collectively, these findings...identify SHP1 and BCL-2 as potential predictive markers for response to treatment with a venetoclax/BCR inhibitor combination.
    DOI:
    10.1182/blood-2018-99-118120